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During the editorial process preceding the publication of
this article an error was introduced in the heading of
“Table 1 Univariate and multivariate analysis of elafin-
positive cells in breast cancer patients.” This error was
only noticed after publication of the final version. Specif-
ically, both data-containing columns are labeled “Elafin
Negative.” The data-containing column on the right
should in fact be labeled “Elafin Positive (n = 482).” The
corrected version can be found here (Table 1). Table 1
has also been updated in the original article to reflect
the correct labeling of the columns.
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Table 1 Univariate and multivariate analysis of elafin-positive
cells in breast cancer patients






Age of diagnosis, year 0.02
Mean 55.5 53.5
Median (range) 55 (26–86) 52 (25–87)
Stage <0.0001
I 120 (38.7) 115 (24.0)
IIA 128 (41.3) 241 (50.2)
IIB 62 (20.0) 124 (25.8)
Unknown 1 2
ER <0.0001
Positive 266 (85.5) 280 (58.3)
Negative 45 (14.5) 200 (41.7)
Unknown 0 2
PR <0.0001
Positive 218 (70.1) 236 (49.2)
Negative 93 (29.9) 244 (50.8)
Unknown 0 2
HER-2 0.013
Positive 42 (13.5) 98 (20.4)
Negative 269 (86.5) 383 (79.6)
Unknown 0 1
Grade <0.0001
I 41 (14.2) 31 (6.8)
II 186 (64.6) 197 (43.5)
III 61 (21.2) 225 (49.7)
Unknown 23 29
Tumor subtype <0.0001
Luminal A 185 (61.9) 158 (33.1)
Luminal B 45 (15.1) 94 (19.8)
Her2 positive 42 (14.0) 98 (20.7)
Triple negative 27 (9.0) 125 (26.4)
Unknown 12 7
Recurrence <0.0001
No 250 (80.9) 298 (62.3)
Yes 59 (19.1) 180 (37.7)
Unknown 2 4
Table 1 Univariate and multivariate analysis of elafin-positive
cells in breast cancer patients (Continued)
B. Multivariate Cox proportional hazards analysis of clinicopathologic
variables’ influence on breast cancer RFS in whole cohort (n = 793)
Factor HR Se P 95% CI
Stage
I referent
IIA 1.67 0.31 0.005 1.17-2.39
IIB 2.41 0.47 <0.0001 1.65-3.52
Age 0.98 0.01 <0.0001 0.97-0.99
Elafin Positive 1.94 0.3 <0.0001 1.44-2.62
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